$QNCX

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Quince Therapeutics, Inc. (the “ Company ”), held a special meeting of stockholders (the “ Special Mee

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “ Resigning Directors ”)

Citizens upgraded Quince Therapeutics (QNCX) to Market Outperform with a $77 price target, citing its rare disease pipeline and undervaluation. The company's LAM-001 drug is in Phase 2 trials for pulmonary diseases, with a potential market of 200,000 patients in the U.S. and Europe. QNCX shares have risen ~94% in six months, and the company plans a stockholder meeting to vote on share issuance.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an a

Quince Therapeutics' President Charles Ryan will leave the company on September 8, 2026, according to an SEC filing. The reason for his departure and any replacement details were not disclosed.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 23, 2026, Quince Therapeutics, Inc. (the “Company”) and Charles Ryan, the Company’s President, determined that M

Quince Therapeutics (Nasdaq: QNCX) reported Q2 2026 results and a corporate update. It completed the stock-for-stock acquisition of Orphai, adding inhaled rapamycin LAM-001 to its pipeline. Quince closed a $115M private placement, with up to $83M more via warrants. Cash was $116M at June 30, 2026, funding operations through end-2028. Net loss was $75.5M.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Conditional Resignations of Dirk Thye and Brendan Hannah On July 29, 2026, each of Dirk Thye, the Chief Executive Officer

Quince Therapeutics (QNCX) seeks stockholder approval for proposals tied to its May 2026 acquisition of Orphai Therapeutics and a concurrent $115 million PIPE. The company says Series C preferred and warrants could convert into up to 16.6 million new common shares versus 1.0 million currently outstanding, implying major dilution. It also warns non-approval could trigger cash settlement.